Latest news with #LDL
Health Line
7 days ago
- Health
- Health Line
Does Salt Intake Raise Your Cholesterol Levels?
While salt doesn't directly raise LDL (low-density lipoprotein) or 'bad' cholesterol levels, it influences conditions that can worsen cholesterol-related conditions. High sodium intake is closely linked to increased blood pressure. When your blood pressure rises, your arteries can become damaged over time. Damaged arteries are more likely to accumulate cholesterol-rich plaques, which can eventually lead to atherosclerosis, heart attack, or stroke. Some research suggests that high salt intake may impact how your body processes fats and cholesterol. For example, a high sodium diet may reduce the effectiveness of medications designed to manage cholesterol and blood pressure. It can also contribute to weight gain due to water retention and increased thirst, which may lead to higher calorie intake. Carrying extra weight, particularly around the abdomen, is a known risk factor for elevated cholesterol levels. If you're managing high cholesterol, it's wise to monitor your sodium intake alongside dietary cholesterol and saturated fats. Processed and packaged foods often contain high levels of salt, saturated fats, and trans fats, creating a compounding effect that can worsen heart health. Take action Focus on whole, unprocessed foods and flavor your meals with herbs, spices, and citrus instead of salt.
The Sun
05-08-2025
- Automotive
- The Sun
JPJEID registration now available at driving institutes nationwide
PUTRAJAYA: The Road Transport Department (JPJ) has expanded JPJEID registration to driving institutes (IMs) nationwide, effective today. This move allows easier access to digital services for learner drivers and other JPJ transactions. JPJ Director-General Datuk Aedy Fadly Ramli stated that JPJEID is an account containing a User ID and password, required for accessing the MySIKAP public portal and the MyJPJ application. 'With JPJEID registration, citizens can carry out 38 types of JPJ transactions online, including services related to driver licensing,' he said in a statement. Aedy Fadly highlighted that individuals who pass the Driving Education Curriculum Test (KPP01) can now apply for a Learner's Driving Licence (LDL) via MySIKAP. 'After successful payment, the LDL licence will be displayed digitally via the MyJPJ application,' he added. The initiative aims to streamline public access to JPJ services and support the department's digital transformation. All learner driving candidates can now register for JPJEID at any IM to conduct transactions through MySIKAP and MyJPJ. - Bernama
Business Standard
28-07-2025
- Business
- Business Standard
Lodha posts 42% YoY rise in Q1 PAT; achieved more than 90% of FY26 business guidance
Lodha has reported 42% rise in consolidated net profit to Rs 674.70 crore on a 22.7% increase in net sales to Rs 3,491.70 crore in Q1 FY26 as compared with Q1 FY25. Total operating expenditure for Q1 FY26 was Rs 2,507.50 crore, up 20% YoY. Profit before tax for the first quarter was Rs 903.50 crore, up by 38.9% from Rs 650.60 crore posted in the same period last year. For the first quarter, the companys pre-sales was Rs 4,450 crore (up 10% YoY) and collections aggregating to Rs 2,880 crore (up 7% YoY). Abhishek Lodha, MD & CEO, Lodha Developers, said: "On the back of interest rate cuts and the benefit from income tax cuts, we are seeing pick up in mid-income demand and we expect this to strengthen in H2 of this FY. We are pleased to share that we have achieved more than 90% of our FY26 business development guidance in the first quarter itself. We added five projects at marquee locations in MMR, Pune and Bengaluru with Rs 227 billion of GDV potential. This takes the total GDV addition since our IPO to more than Rs 1 trillion, spread across 48 projects." He further informed that despite the significant investments in business development in this quarter, the companys net debt stood at Rs 50.8 billion (0.24x net debt/ equity) - well below the ceiling of 0.5x net debt/equity. The companys exit cost of debt for Q1 FY26 stood at 8.3% (down 40 bps for the quarter), which is among the lowest in the industry. Lodha Developers (LDL), formerly Macrotech Developers, is one of Indias largest real estate developers, holding a market-leading position in Mumbai and Thane. Focused on residential projects across MMR, Pune, and Bengaluru, the company holds one of the largest land banks in India, spanning 600 million square feet. The scrip declined 3.11% to currently trade at Rs 1239.50 on the BSE.
25-07-2025
- Health
Should you take a statin? What to know
ABC News' Dr. Tara Narula explains why some people are hesitant to take statins, which may be recommended when lifestyle changes aren't enough to lower LDL cholesterol. July 25, 2025
Yahoo
22-07-2025
- Business
- Yahoo
Esperion to Report Second Quarter 2025 Financial Results on August 5
ANN ARBOR, Mich., July 22, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2025 financial results before the market opens on Tuesday, August 5, 2025. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days. Esperion TherapeuticsEsperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms. Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit and follow Esperion on LinkedIn and X. Esperion Contact Information: Investors: Alina Veneziainvestorrelations@ (734) 887-3903 Media: Tiffany Aldrich corporateteam@ (616) 443-8438Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
